Last Updated : April 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Adtralza | tralokinumab | atopic dermatitis (AD) | Active | |||
| Akeega | niraparib abiraterone acetate | Metastatic castration-resistant prostate cancer (mCRPC) | Reimburse with clinical criteria and/or conditions | Active | ||
| Livmarli | maralixibat | Alagille syndrome | Active | |||
| Veklury | remdesivir | COVID-19 in hospitalized patients | Active | |||
| Veklury | remdesivir | COVID-19 in non-hospitalized patients | Active | |||
| TBC | zilucoplan | Generalized myasthenia gravis (gMG) | Active | |||
| Olumiant | baricitinib | Alopecia areata, severe | Active | |||
| Trikafta | elexacaftor/tezacaftor/ivacaftor and ivacaftor | Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older | Active | |||
| TBC | clindamycin plus benzoyl peroxide and adapalene | acne vulgaris | Active | |||
| Dificid | fidaxomicin | Clostridium difficile infection | Active |
Last Updated : April 20, 2024